JP2022538609A5 - - Google Patents
Info
- Publication number
- JP2022538609A5 JP2022538609A5 JP2021577385A JP2021577385A JP2022538609A5 JP 2022538609 A5 JP2022538609 A5 JP 2022538609A5 JP 2021577385 A JP2021577385 A JP 2021577385A JP 2021577385 A JP2021577385 A JP 2021577385A JP 2022538609 A5 JP2022538609 A5 JP 2022538609A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- cells
- antigen
- sequence
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024197303A JP2025032114A (ja) | 2019-06-28 | 2024-11-12 | 新規な癌抗原及び方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19183396.1 | 2019-06-28 | ||
| EP19183396 | 2019-06-28 | ||
| PCT/GB2020/051558 WO2020260898A2 (en) | 2019-06-28 | 2020-06-26 | Novel cancer antigens and methods |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024197303A Division JP2025032114A (ja) | 2019-06-28 | 2024-11-12 | 新規な癌抗原及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022538609A JP2022538609A (ja) | 2022-09-05 |
| JP2022538609A5 true JP2022538609A5 (enExample) | 2023-07-18 |
Family
ID=67145533
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021577385A Pending JP2022538609A (ja) | 2019-06-28 | 2020-06-26 | 新規な癌抗原及び方法 |
| JP2024197303A Pending JP2025032114A (ja) | 2019-06-28 | 2024-11-12 | 新規な癌抗原及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024197303A Pending JP2025032114A (ja) | 2019-06-28 | 2024-11-12 | 新規な癌抗原及び方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220218807A1 (enExample) |
| EP (1) | EP3990007A2 (enExample) |
| JP (2) | JP2022538609A (enExample) |
| KR (1) | KR20220029560A (enExample) |
| CN (2) | CN119119228A (enExample) |
| AU (1) | AU2020307943A1 (enExample) |
| BR (1) | BR112021026375A2 (enExample) |
| CA (1) | CA3141229A1 (enExample) |
| IL (1) | IL289205A (enExample) |
| MX (1) | MX2021015766A (enExample) |
| WO (1) | WO2020260898A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021006941A2 (pt) | 2018-10-19 | 2021-08-31 | The Francis Crick Institute Limited | Antígenos de câncer inovadores e métodos |
| BR112021025943A2 (pt) * | 2019-06-25 | 2022-02-08 | Univ Montreal | Antígenos específicos de tumor inovadores para câncer de ovário e usos dos mesmos |
| WO2022229647A1 (en) | 2021-04-28 | 2022-11-03 | Enara Bio Limited | Novel cancer antigens and methods |
| WO2025133007A1 (en) | 2023-12-19 | 2025-06-26 | Enara Bio Limited | Novel cancer antigens and methods |
| WO2025202937A1 (en) | 2024-03-26 | 2025-10-02 | BioNTech SE | Cancer vaccines |
| WO2025224446A1 (en) | 2024-04-23 | 2025-10-30 | Enara Bio Limited | Novel cancer antigens and methods |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0871747A1 (en) | 1996-01-02 | 1998-10-21 | Chiron Viagene, Inc. | Immunostimulation mediated by gene-modified dendritic cells |
| US6488931B1 (en) * | 1998-12-17 | 2002-12-03 | Corixa Corporation | Compositions and methods for therapy and diagnosis of ovarian cancer |
| DK1871391T3 (da) | 2005-03-30 | 2012-04-16 | Viroxis | Endogen retrovirus og proteiner, der kodes af env som target for cancerbehandling |
| US8921050B2 (en) | 2006-03-17 | 2014-12-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of diagnosing renal cell carcinoma |
| US20080019979A1 (en) | 2006-05-22 | 2008-01-24 | Feng Wang-Johanning | HERV-K Antigens, Antibodies, and Methods |
| US20090297530A1 (en) * | 2006-05-22 | 2009-12-03 | Feng Wang-Johanning | Herv-k antigens, antibodies, and methods |
| WO2013040142A2 (en) * | 2011-09-16 | 2013-03-21 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
| WO2014004385A2 (en) * | 2012-06-25 | 2014-01-03 | Board Of Regents, The University Of Texas System | Anti-cancer vaccines |
| CN110248645B (zh) * | 2016-12-29 | 2022-04-26 | 韩国科学技术研究院 | 基于外来体的抗癌剂 |
| KR101964124B1 (ko) * | 2017-03-28 | 2019-04-01 | 한국과학기술연구원 | 히알유로니데이즈 포함 신규 재조합 엑소좀 및 그의 용도 |
| KR101869518B1 (ko) * | 2018-03-28 | 2018-06-20 | 황인후 | 췌장암 줄기세포의 emt-met 가소성을 이용한 암 치료용 수지상 세포 백신의 제조 방법 |
| BR112021025943A2 (pt) * | 2019-06-25 | 2022-02-08 | Univ Montreal | Antígenos específicos de tumor inovadores para câncer de ovário e usos dos mesmos |
-
2020
- 2020-06-26 EP EP20735234.5A patent/EP3990007A2/en active Pending
- 2020-06-26 MX MX2021015766A patent/MX2021015766A/es unknown
- 2020-06-26 CA CA3141229A patent/CA3141229A1/en active Pending
- 2020-06-26 CN CN202410989999.0A patent/CN119119228A/zh active Pending
- 2020-06-26 BR BR112021026375A patent/BR112021026375A2/pt not_active IP Right Cessation
- 2020-06-26 KR KR1020217039989A patent/KR20220029560A/ko not_active Ceased
- 2020-06-26 AU AU2020307943A patent/AU2020307943A1/en not_active Abandoned
- 2020-06-26 CN CN202080047135.7A patent/CN114341168A/zh active Pending
- 2020-06-26 JP JP2021577385A patent/JP2022538609A/ja active Pending
- 2020-06-26 WO PCT/GB2020/051558 patent/WO2020260898A2/en not_active Ceased
-
2021
- 2021-12-17 US US17/644,923 patent/US20220218807A1/en active Pending
- 2021-12-21 IL IL289205A patent/IL289205A/en unknown
-
2024
- 2024-11-12 JP JP2024197303A patent/JP2025032114A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022538609A5 (enExample) | ||
| Kawashima et al. | Identification of GP100‐derived, melanoma‐specific cytotoxic T‐lymphocyte epitopes restricted by HLA‐A3 supertype molecules by primary in vitro immunization with peptide‐pulsed dendritic cells | |
| JP2014521657A (ja) | 膵臓がんに対する樹状細胞（ｄｃ）ワクチン療法 | |
| CN106243213B (zh) | 一种肿瘤相关抗原XAGE-1b短肽及应用 | |
| JP2022539585A5 (enExample) | ||
| CN109970846A (zh) | 一种肿瘤相关抗原XAGE-1b九肽及其应用 | |
| JP2022540396A5 (enExample) | ||
| CN114341169B (zh) | 新的癌抗原和方法 | |
| JP2022539157A5 (enExample) | ||
| JP2022514116A5 (enExample) | ||
| CN112867501B (zh) | 新的癌抗原和方法 | |
| CN106279392B (zh) | 肿瘤相关抗原XAGE-1b短肽及其应用 | |
| Llopiz et al. | Inhibition of adjuvant-induced TAM receptors potentiates cancer vaccine immunogenicity and therapeutic efficacy | |
| JP2011506497A5 (enExample) | ||
| Smith et al. | Immunotherapy of melanoma | |
| CN104837497B (zh) | 用于预防和治疗HPV-相关的肿瘤和其它表达p16的肿瘤的p16INK4a衍生肽 | |
| JP2022501046A (ja) | アルギナーゼ１ポリペプチド | |
| Sennikov et al. | Induction of an antitumor response using dendritic cells transfected with DNA constructs encoding the HLA-A* 02: 01-restricted epitopes of tumor-associated antigens in culture of mononuclear cells of breast cancer patients | |
| CN104341530A (zh) | Vnsak多肽及其应用 | |
| EP2573105B1 (en) | p16INK4a derived peptides for prophylaxis and therapy of HPV-associated tumors and other p16INK4a expressing tumors | |
| WO2021209775A1 (en) | Antigen pool | |
| US9566319B2 (en) | p16INK4a derived peptides for prophylaxis and therapy of HPV-associated tumors and other p16INK4a expressing tumors | |
| Mizote et al. | Three novel NY-ESO-1 epitopes bound to DRB1* 0803, DQB1* 0401 and DRB1* 0901 recognized by CD4 T cells from CHP-NY-ESO-1-vaccinated patients | |
| JP2014117194A (ja) | ＨＰＶ関連腫瘍及び他のｐ１６ＩＮＫ４ａ発現腫瘍の予防法及び治療法のためのｐ１６ＩＮＫ４ａ由来ペプチド | |
| KR101203979B1 (ko) | Ｒｎａ 전이 항원 제시 세포를 이용한 신규 종양항원의 규명 방법 |